Enting R H, Lensing A W, de Visser B W
Academisch Medisch Centrum, afd. Neurologie en Klinische Neurofysiologie, Amsterdam.
Ned Tijdschr Geneeskd. 1998 Feb 28;142(9):436-8.
Current drug treatment of Bell's palsy often consists of prednisone for patients with a complete paralysis. Since it was demonstrated that herpes simplex plays a role in the pathogenesis of Bell's palsy, antiviral therapy may become the treatment of choice. Six randomized controlled trials comparing prednisone with placebo have been performed: four of them did not conform to the criteria for good clinical trials. The remaining two trials did not demonstrate therapeutic efficacy of prednisone. A recently published randomized controlled trial comparing prednisone and acyclovir with prednisone and placebo showed a statistically significant and clinically important superiority of the combination therapy. This trial, however, also had methodological flaws and its results should be interpreted with caution. In our opinion, further evidence is needed before acyclovir should be given routinely to patients with Bell's palsy.
目前针对贝尔面瘫的药物治疗,对于完全性面瘫患者通常采用泼尼松。自从有证据表明单纯疱疹在贝尔面瘫的发病机制中起作用后,抗病毒治疗可能会成为首选治疗方法。已经进行了六项比较泼尼松与安慰剂的随机对照试验:其中四项不符合良好临床试验的标准。其余两项试验未证明泼尼松具有治疗效果。最近发表的一项随机对照试验比较了泼尼松与阿昔洛韦联合治疗和泼尼松与安慰剂治疗,结果显示联合治疗在统计学上具有显著意义且在临床上具有重要优势。然而,该试验也存在方法学缺陷,其结果应谨慎解读。我们认为,在将阿昔洛韦常规用于贝尔面瘫患者之前,还需要进一步的证据。